COVID-19 Vaccine Of Moderna Shows Good Efficacy In Clinical Trials by Pooja Shete on January 1, 2021 at 7:27 PM
Data from the much-anticipated COVE study, which evaluated mRNA-1273, a vaccine candidate against COVID-19 manufactured by Moderna, Inc, provides evidence that the vaccine can prevent symptomatic infection. The study will continue for two years more.
The trial which evaluated more than 30,000 participants randomized to receive the vaccine or a placebo showed that 11 participants in the vaccine group developed symptomatic COVID-19 when compared to 185 participants who received the placebo. The vaccine showed an efficacy of 94.1 percent in preventing symptomatic COVID-19. Only in one participant a severe case of COVID-19 was seen.
Zydus Cadila COVID-19 Vaccine Found Safe in Clinical Trials by Colleen Fleiss on December 24, 2020 at 11:33 PM
In the phase I and II clinical trials, Zydus Cadila announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D, was found to be safe, well tolerated and immunogenic.
The company is now planning to initiate phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals.
The phase II study of the vaccine ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study. The vaccine was found to be safe and immunogenic.